Large-scale preparation of active caspase-3 in E. coli by designing its thrombin-activatable precursors by Kang, Hyo Jin et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Biotechnology
Open Access Research article
Large-scale preparation of active caspase-3 in E. coli by designing its 
thrombin-activatable precursors
Hyo Jin Kang1,2, Young-mi Lee2, Yu-Jin Jeong1,2, Kyoungsook Park2, Mi Jang3, 
Sung Goo Park3, Kwang-Hee Bae3, Moonil Kim1,2 and Sang J Chung*1,2
Address: 1Nanobiotechnology Division, University of Science and Technology (UST), Yuseong, Daejeon, 305-806, Korea, 2BioNanotechnology 
Research Center, KRIBB, Yuseong, Daejeon, 305-806, Korea and 3Translational Research Center, KRIBB, Yuseong, Daejeon, 305-806, Korea
Email: Hyo Jin Kang - jin0305@kribb.re.kr; Young-mi Lee - utopia19@kribb.re.kr; Yu-Jin Jeong - pipini_2002@hanmail.net; 
Kyoungsook Park - marsp@hanmail.net; Mi Jang - rosemb@kribb.re.kr; Sung Goo Park - sgpark@kribb.re.kr; Kwang-
Hee Bae - khbae@kribb.re.kr; Moonil Kim - kimm@kribb.re.kr; Sang J Chung* - sjchung@kribb.re.kr
* Corresponding author    
Abstract
Background:  Caspase-3, a principal apoptotic effector that cleaves the majority of cellular
substrates, is an important medicinal target for the treatment of cancers and neurodegenerative
diseases. Large amounts of the protein are required for drug discovery research. However,
previous efforts to express the full-length caspase-3 gene in E. coli have been unsuccessful.
Results: Overproducers of thrombin-activatable full-length caspase-3 precursors were prepared
by engineering the auto-activation sites of caspase-3 precursor into a sequence susceptible to
thrombin hydrolysis. The engineered precursors were highly expressed as soluble proteins in E. coli
and easily purified by affinity chromatography, to levels of 10–15 mg from 1 L of E. coli culture, and
readily activated by thrombin digestion. Kinetic evaluation disclosed that thrombin digestion
enhanced catalytic activity (kcat/KM) of the precursor proteins by two orders of magnitude.
Conclusion: A novel method for a large-scale preparation of active caspase-3 was developed by
a strategic engineering to lack auto-activation during expression with amino acid sequences
susceptible to thrombin, facilitating high-level expression in E. coli. The precursor protein was easily
purified and activated through specific cleavage at the engineered sites by thrombin, generating
active caspase-3 in high yields.
Background
Multicellular organisms maintain homeostasis through a
balance between cell proliferation and death. Apoptosis is
a controlled cell death process crucial in a wide range of
biological activities, such as normal cell turnover,
immune system, embryonic development, metamorpho-
sis, and chemical-dependent cell death [1]. Neuronal
death due to aberrant apoptosis underlies the symptoms
of various neurological disorders, such as Alzheimer's,
Parkinson's and Huntington's diseases, stroke, amyo-
tropic lateral sclerosis (ALS), multiple sclerosis (MS) and
spinal muscular atrophy [2]. On the other hand, inactiva-
tion of apoptosis by blocking upstream death signals or
inhibition of caspase activity by IAP complex formation is
central to cancer development and cellular resistance of
cells against anticancer agents [3-5].
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Caspases, a family of cysteine proteases, play crucial roles
in apoptosis, pro-inflammatory cytokine activation, and
presumably, keratinocyte differentiation [6,7]. Following
the initial identification of caspase-1 in 1992 by two dif-
ferent groups [8,9], eleven caspases in humans and 25 in
other eukaryotes have been characterized over the last
decade [10]. In mammals, caspases are translated as inac-
tive zymogens. While caspases-8 and -10 are activated by
death receptor-mediated signals (extrinsic apoptosis path-
way), caspase-9 activity is stimulated by intracellular
death signals, including cytochrome c released from mito-
chondria (intrinsic apoptosis pathway). Activated cas-
pases subsequently convert procaspase-3 and -7 to fully
active enzymes by specific proteolytic cleavage. Caspase-6
is activated after caspase-3. The three former caspases are
known as apoptotic initiators, whereas the latter three are
known as apoptotic effectors or executioners. Caspase-3
(also designated CED-3, murine ICE, and a protease
resembling ICE/CPP32 in humans) is the first reported
apoptotic effector, and cleaves the majority of cellular
substrates in apoptotic cells [11-14]. Caspase-7 is very
similar to caspase-3 in terms of structure and substrate
specificity [6]. As caspase-3 and -7 are the final execution-
ers of apoptosis, both inhibition and activation of cata-
lytic activities are of significant interest as therapeutic
strategies for neurodegenerative diseases and cancers
[5,15-18].
Drug discovery research, including screening chemical
libraries as well as structural and kinetic analyses, requires
large-scale caspase-3 preparation. When expressed in E.
coli, full-length caspase-3 (procaspase-3) undergoes pre-
sumable autoprocessing to yield the appropriate subunits
characteristic of the active enzyme with only a marginal
expression level, probably due to its cytotoxicity [19].
While full-length caspase-3 has been expressed in Pichia
pastoris [20], the process is long and the yield is inade-
quate, compared to conventional protein expression
method in E. coli. The most frequently employed large-
scale caspase-3 preparation method includes separate
expression of the two insoluble domains in E. coli and
subsequent refolding of the two combined domains for
the active enzyme [21]. This method showed significantly
improved protein yield. However, such a costly and time-
consuming refolding process is unsuitable for efficient
large-scale production for drug discovery research. Here
we describe a novel method for high-level expression and
purification of caspase-3 precursors. The precursor was
strategically engineered to lack auto-activation during
expression with amino acid sequences susceptible to
thrombin, facilitating high-level expression in E. coli. The
precursor protein was activated through specific cleavage
at the engineered sites by thrombin, generating active cas-
pase-3. Furthermore, this protein efficiently digested
endogenous caspase-3 substrate.
Results and discussion
Design of thrombin-activatable caspase-3 precursors for 
high-level expression in E. coli
Caspases are translated in cells as inactive precursors,
which are sequentially activated following internal or
external cell death signals. Apoptotic initiators, such as
caspases-8, -9 and -10, activated procaspases-3 and -7 by
specific hydrolysis, thereby triggering cell death by specific
apoptotic executioners [1,6,7]. During activation, procas-
pase-3 cleavage occurs at three sites, specifically, the C-ter-
minal peptide bonds of Asp-9, Asp-28 and Asp-175 (Fig.
1A). As stated above, full activation of caspase-3 during
overexpression in E. coli hampers large-scale preparation
with conventional methods [19]. We planned to substi-
tute the cleavage sites with specific peptide sequences that
were resistant to caspase but susceptible to thrombin (Fig.
1A). Consequently, the precursor protein is not activated
during expression, but stimulated by thrombin at a con-
venient time. The mutations designed included replace-
ment of cleavage sites with LVPRGS, a well-known
thrombin substrate sequence, and insertion of this
sequence near cleavage sites with appropriate mutations
of the cleavage site. Since procaspase-3 releases the N-ter-
minal 28 amino acids during the activation, the matured
caspase-3 (active caspase-3) does not have these 28 amino
acids in its structure. Therefore, the constructs that lack the
N-terminal 28 amino acids were prepared. Δ28-caspase-3
(II) was depleted of 28 amino acids at the N-terminus of
procaspase-3 (I), while Δ28/175TS-caspase-3 (III) con-
tained LVPRGS instead of wild-type residues at positions
172–177 of construct II (Fig. 1B). In the 28TS/175TS-cas-
pase-3 construct (IV), LVPRGS mutations were introduced
at two sites (positions 25–30 and 172–177) of wild-type
caspase-3 (I). In 28TS/180TI-caspase (V), the LVPRGS
motif replaced residues 25–30, and was inserted between
Asp180 and Asp181, along with a D175A mutation to pre-
vent auto-cleavage. Since caspase-3 activation occurs
mainly via cleavage at Asp 28 and 175, constructs were
designed to ensure cleavage by thrombin at the corre-
sponding sites (between R and G of LVPRGS). The
LVPRGS motif was inserted between Asp180 and 181 in
28TS/180TI-caspase (V) to maintain the structural integ-
rity of the sequence encompassing residues 165–174 after
cleavage, in view of the crystal structure of active caspase-
3, which discloses tight interactions between this region
and the other dimer within a heterotetrameric arrange-
ment [22].
Expression and purification of the engineered caspase-3 
precursors
Proteins were expressed in E. coli BL21 Rosetta (Novagen),
and purified by cobalt affinity chromatography. Com-
pared with wild-type, engineered proteins III, IV and V
were highly expressed (Fig. 2A) and purified up to levels
of 10–15 mg from 1 L E. coli culture. Interestingly, proteinBMC Biotechnology 2008, 8:92 http://www.biomedcentral.com/1472-6750/8/92
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V  displayed severe fragmentation during expression,
despite the removal of known cleavage sites by site-
directed mutagenesis. Since catalytically inactive C163S
caspase-3 did not show a significant cleavage during
expression, we suspected that self-catalysis by the precur-
sor proteins is responsible for cleavage of proteins V.
Hence, purified precursors were treated with catalytically
active caspase-3 to establish whether auto-processing by
precursor proteins was eliminated by mutation. While the
C163S precursor protein was cleaved into two small frag-
ments, no significant fragmentation was evident with the
other proteins including protein V, implying that muta-
tion of auto-cleavage sites blocks the auto-processing of
caspase-3 precursors during expression (Fig. 2B). This
finding also suggests that the cleavage of protein V in E.
coli  does not result from caspase activity, but that of
another protease.
Activation of engineered caspase-3 precursors
Purified proteins III and IV, together with the catalytically
inactive C163S caspase-3 precursor, were treated with
thrombin. As shown in Fig. 2C, ~30 kDa single polypep-
tides of III and IV were cleaved into two smaller peptides
with molecular weights of 12 and 17 kDa (lanes 2 and 4),
respectively. However, the C163S caspase-3 precursor did
not display significant cleavage under similar conditions
(lanes 7 and 8), indicating that fragmentation of III and
IV is due to specific thrombin activity at the mutated sites.
Notably, the cleavage sites of protein V during expression
were distinct to those of thrombin. These specific sites
remain to be identified. Since engineered caspase-3 pre-
cursors have His6-tag at their C-terminus, the thrombin
can be easily removed by cobalt affinity chromatography
after activation of caspase-3 (data not shown). Next, the
size and activity of activated engineered caspases were
compared with endogenous active caspase-3 using PAGE
analysis. As shown in Fig. 3A, all engineered caspases acti-
vated by thrombin treatment were detected at similar
position to endogenous active caspase-3. Furthermore,
proteins VI and VIII cleaved PARP, a well-known sub-
strate of caspase-3, at the similar level to wild-type cas-
pase-3 (Fig. 3B).
Kinetic analysis of caspase-3 precursors and activated 
proteins
The kinetic properties of caspase-3 precursors and their
activated proteins were characterized using a commer-
cially available synthetic substrate (Ac-DEVD-pNA). The
engineered protein precursors III  and  IV  containing
LVPRGS exhibited negligible catalytic activity (no higher
than 0.1% that of the wild-type enzyme). Thrombin
digestion of proteins III  and  IV  resulted in a drastic
increase in catalytic activity (almost by two orders of mag-
nitude), in agreement with a previous report [23] (Table
1). For example, kcat/KM values representing the substrate
specificities of IV and VII were determined as 1.7 × 102 M-
High-level expression of caspase-3 precursors in E. coli Figure 1
High-level expression of caspase-3 precursors in E. coli. A. Design of thrombin-activatable caspase-3 precursors resist-
ant to autoactivation. B. Structure of designed proteins. I: wild-type caspase-3; II: caspase-3 devoid of the N-terminal 28 amino 
acids; III: Six amino acids (172–177) of construct II were substituted with LVPRGS (a sequence susceptible to thrombin activ-
ity); IV: Two sites (amino acid sequences 25–30 and 172–177) of wild-type caspase-3 were replaced with LVPRGS. V: Six amino 
acids (172–177) of wild-type caspase-3 were mutated to LVPRGS, and an additional LVPRGS motif inserted between Asp180 
and Asp181. Asp175 was mutated to Ala.BMC Biotechnology 2008, 8:92 http://www.biomedcentral.com/1472-6750/8/92
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1s-1 and 2.9 × 104 M-1s-1, respectively. The kcat/KM value of
protein V containing an insertion of the LVPRGS motif
between D180 and D181 was calculated as 6.7 × 104 M-1s-
1, which was not significantly increased upon thrombin
digestion. The data indicate that protein V is already acti-
vated during expression. This finding is supported by SDS-
SDS-PAGE analysis of engineered caspase-3 proteins Figure 2
SDS-PAGE analysis of engineered caspase-3 proteins. A. Expression and Western blot analysis of engineered caspase-3 
proteins. Cell lysates (20 μg) were prepared using an identical method, and loaded onto each well. M, molecular weight size 
marker; lane 1, uninduced E. coli lysate expressing wild-type caspase-3; lane 2, IPTG-induced E. coli lysate expressing wild-type 
caspase-3 (I); lane 3, IPTG-induced E. coli lysate expressing Δ28-caspase-3 (II); lane 4, IPTG-induced E. coli lysate expressing 
Δ28/175TS-caspase-3 (III); lane 5, IPTG-induced E. coli lysate expressing 28TS/175TS-caspase-3 (IV); lane 6, IPTG-induced E. coli 
lysate expressing 28TS/180TI-caspase-3 (V). The right and left images were obtained after coomassie blue staining and Western 
blot analysis, respectively. B. Treatment of caspase-3 precursors with wild-type caspase-3 (I). After each caspase-3 precursor 
was treated with wild-type caspase-3 (I) at RT for 18 h, 20 μl of each sample was heat-denatured and analyzed by SDS-PAGE. 
M, molecular weight size marker; lane 1, III; lane 2, III processed with I; lane 3, IV; lane 4, IV processed with I; lane 5, V; lane 6, 
V processed with I; lane 7, C163S caspase-3; lane 8, C163S caspase-3 treated with I. C. Activation of caspase-3 precursors by 
thrombin. Caspase-3 precursors were treated with thrombin at 4°C for 18 h, and 20 μl of each sample was heat-denatured and 
analyzed using PAGE. M, molecular weight size marker; lane 1, III; lane 2, III processed with thrombin (VI); lane 3, IV; lane 4, IV 
processed with thrombin (VII); lane 5, V; lane 6, V processed with thrombin (VIII); lane 7, C163S caspase-3; lane 8, C163S cas-
pase-3 processed with thrombin.BMC Biotechnology 2008, 8:92 http://www.biomedcentral.com/1472-6750/8/92
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PAGE analysis results showing four smaller bands instead
of the 30 kDa protein (Fig. 2A). Considering that Sten-
nicke  et al. attributed the marginal expression level of
active caspase-3 in E. coli to the cytotoxicity of active cas-
pase-3 [19], it was unexpected result. As the peptide sizes
of protein V  were further altered by digestion with
thrombin but not wild-type caspase-3, we propose that
cleavage during expression is attributed to the activity of
another protease in E. coli. The present results are incon-
sistent with previous reports showing that uncleavable
procaspase-3 mutants do not show this type of cleavage or
meaningful activity [22]. It is envisaged that insertion of
the LVPRGS peptide induces a structural change in procas-
pase-3 to some degree. Given that the catalytic cysteine
shifts to an insignificant extent before and after the activa-
tion of caspase-7 [24], insertion of 6 amino acids into the
loop containing catalytic Cys163 may be sufficient for its
rearrangement to induce an active state, even without
cleavage.
Significant changes in kcat, rather than KM values induced
by mutation or activation resulted in similar substrate
binding in all protein mutants, but altered catalytic activ-
ity. The KM and kcat values of protein III were 93.2 μM and
Comparison of engineered caspases with endogenous caspase-3 and cleavage of PARP by engineered caspases Figure 3
Comparison of engineered caspases with endogenous caspase-3 and cleavage of PARP by engineered caspases. 
A. Western blot analysis using anti-caspase-3 antibody. H, unstimulated HL-60 cell lysate; E, HL-60 cell lysate stimulated with 
etoposide; lane 1, purified wild-type caspase-3 (I); lane 2, purified II; lane 3, purified III; lane 4, VI; lane 5, purified IV; lane 6, VII; 
lane 7, purified V; lane 8, VIII. B. Western blot analysis of PARP cleavage by wild-type and engineered caspases (VI and VIII). HL-
60 cell lysates were treated with each caspase in the presence and absence of caspase-3 inhibitor (z-DEVD-fmk) and Western 
blot analysis was carried out using an anti-PARP antibody which recognizes the full length (115 kDa) PARP and its cleavage 
product (24 kDa). H, unstimulated HL-60 cell lysate; E, HL-60 cell lysate stimulated with etoposide.BMC Biotechnology 2008, 8:92 http://www.biomedcentral.com/1472-6750/8/92
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0.05 s-1, while those of VI were 41.3 μM and 1.86 s-1,
respectively. The data correspond to 2.3 and 37.2-fold
changes in substrate binding affinity and catalytic activity,
respectively, upon activation. These findings imply that
mutation or activation processes do not significantly alter
the global shape of the active site, but affect the spatial
arrangement of catalytic Cys163, in agreement with a pre-
vious report showing that activation of caspase-7 leads to
rearrangement of a loop containing the catalytic cysteine
[24].
Conclusion
In this study, we demonstrate a novel strategy for a large-
scale preparation of active caspase-3 in E. coli. Thrombin-
activatable caspase-3 precursors were designed to suppress
autoprocessing, and their activation regulated by
thrombin. The designed precursors were highly expressed
in E. coli, easily purified, and activated by thrombin diges-
tion, yielding 10–15 mg of active caspase-3 from 1 L of E.
coli culture. Following thrombin activation, catalytic activ-
ity was increased about 100-fold, analogous to previous
findings on the wild-type precursor and mature caspase-3
protein. This research represents the first example to
highly express a full-length caspase-3 as a soluble protein
in E. coli, facilitating a large-scale preparation of active cas-
pase-3. This system may be effectively applied to prepare
other caspases on a large scale.
Methods
Materials
Primer synthesis and DNA sequencing were performed by
Bioneer (Daejeon, Korea) and Genotech (Daejeon,
Korea), respectively. The primers used for plasmid con-
struction are listed in Table 2. The caspase substrate, Ac-
DEVD-pNA, was purchased from Anaspec, and thrombin
from Roche. Protein expression and cleavage were moni-
tored by 15% SDS-PAGE analysis. Caspase activity was
measured by monitoring the absorption changes at 405
nm, based on the release of p-nitroanilide from substrate
hydrolysis, on a DU 800 UV-VIS spectrophotometer
(Beckman Coulter). Amino acid sequences of the engi-
neered proteins were numbered based on wild-type pro-
caspase-3.
Generation of caspase-3-overexpressing constructs
Wild-type caspase-3 gene was amplified using the forward
primer, 5'-GGGAATTCCATATGGAGAACACTGAAAACT-
CAG-3' (P1) containing an NdeI site (marked in bold type
letters), and reverse primer, 5'-CCGCTCGAGGTGA-
TAAAAATAGAGTTCTTTTGT-3' (P2), with a XhoI site
(underlined), and inserted into the corresponding sites of
the pET21a plasmid (Novagen). The resulting construct
was designated plasmid I. A Δ28 caspase-3 deletion
mutant devoid of the N-terminal 28 amino acids of wild-
type caspase-3 (I) was prepared using the forward primer,
Table 1: Catalytic parameters of the caspase-3 mutants
ID Caspase KM(μM) kcat(s-1) kcat/KM (M-1s-1)
I Wild type 14.16 ± 1.5 7.21 ± 0.93 (5.0 ± 0.1) × 105
II Δ28 16.38 ± 3.6 3.39 ± 0.58 (2.1 ± 0.1) × 105
III Δ28/175TS 93.20 ± 33.2 0.05 ± 0.02 (5.0 ± 0.0) × 102
IV 28TS/175TS 93.49 ± 9.2 0.02 ± 0.00 (1.7 ± 0.0) × 102
V 28TS/180TI 18.09 ± 1.3 1.26 ± 0.03 (6.7 ± 0.9) × 104
VI Δ28/175TS processed with thrombin 41.13 ± 1.9 1.86 ± 0.09 (4.5 ± 0.0) × 104
VII 28TS/175TS processed with thrombin 27.81 ± 5.7 0.78 ± 0.06 (2.9 ± 0.4) × 104
VIII 28TS/180TI processed with thrombin 21.39 ± 1.9 1.77 ± 0.13 (8.3 ± 0.1) × 104
Table 2: PCR primers used for plasmid construction
Primer 5' → 3'
P1 GGGAATTCCATATGGAGAACACTGAAAACTCAG
P2 CCGCTCGAGGTGATAAAAATAGAGTTCTTTTGT
P3 GGGAATTCCATATGTCTGGAATATCCCTGGACAACAGT
P4 ATCAACGCTGCCGCGCGGCACCAGGCCACAGTCCAGTTCTGTACCACG
P5 TGTGGCCTGGTGCCGCGCGGCAGCGTTGATGATGACATGGCGTGTCAT
P6 ACTGTTGTCCAGGGATATGCTGCCGCGCGGCACCAGGCTTCCATGTATGATCTT
P7 GACTGTGGCATTGAGACAGCGAGTGGTGTTGATGAT
P8 CAGATCATCAACACCACTCGCTGTCTCAATGCCACA
P9 ACAGACAGTGGTGTTGATGATCTGGTGCCGCGCGGCAGCGACATGGCGTGTCATAAA
P10 ACAGACAGTGGTGTTGATGATCTGGTGCCGCGCGGCAGCGACATGGCGTGTCATAAA
* NdeI restriction sites in P1 and P3, and XhoI site in P2 are underlined. Thrombin recognition sites in P4, P5, P6, P9 and P10 and Ala mutations in 
P7 and P8 are italicized.BMC Biotechnology 2008, 8:92 http://www.biomedcentral.com/1472-6750/8/92
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5'-GGGAATTCCATATGTCTGGAATATCCCT-
GGACAACAGT-3' (P3) with an NdeI site (marked in bold
type letters), and reverse primer, P2. The resulting DNA
was inserted into the pET21a expression vector, and
denoted plasmid II. For preparation of Δ28/175TS cas-
pase-3, the 175TS mutant of plasmid I was initially pre-
pared using the megaprimer PCR method with slight
modifications [25]. N-terminal megaprimer DNA encod-
ing amino acids 1~177, which is substituted at positions
172~177 (IETDSG) with LVPRGS, was prepared using the
forward primer, P1, and reverse primer, 5'-
ATCAACGCTGCCGCGCGGCACCAGGCCACAGTC-
CAGTTCTGTACCACG-3' (P4). C-terminal megaprimer
DNA substituted at positions 172–177 (IETDSG) with
LVPRGS was prepared using the forward primer, 5'-TGT-
GGCCTGGTGCCGCGCGGCAGCGTTGATGATGACAT-
GGCGTGTCAT-3', (P5) and reverse primer, P2. The
thrombin recognition sites in P4 and P5 are italicized.
Each megaprimer was extended by PCR, using the other as
a template. The resulting DNA was inserted into pET21a
using the NdeI and XhoI restriction sites, and designated
plasmid IX. The Δ28/175TS caspase-3 mutant of plasmid
IX was prepared using forward P3 and reverse P2 primers.
The amplified product was inserted into the NdeI and XhoI
sites of pET21a, and the construct denoted plasmid III.
For generating the 28TS/175TS mutant caspase-3 con-
struct in plasmid IX, the megaprimer with substitutions at
positions 24–30 (LVPRGS in place of ESMDSG) was pre-
pared using the forward primer, P1, and reverse primer,
5'-ACTGTTGTCCAGGGATATGCTGCCGCGCGGCAC-
CAGGCTTCCATGTATGATCTT-3' (P6). The thrombin rec-
ognition site in P6 is italicized. The resulting megaprimer,
in combination with P2, was applied for the next PCR
reaction to prepare 28TS/175TS caspase-3 DNA, which
was cloned into pET21a, and designated plasmid IV. The
28TS/D175A/180TI caspase-3 construct was generated in
plasmid I using a combination of megaprimer PCR and
the QuikChange site-directed mutagenesis kit (Strata-
gene). To prepare the 28TS caspase-3 construct in plasmid
I, a corresponding megaprimer produced using the P1 for-
ward and P6 reverse primers was employed together with
P2. The resulting construct was designated plasmid X. A
28TS/D175A caspase-3 construct in plasmid X was pre-
pared with the QuikChange kit using the forward primer,
5'-GACTGTGGCATTGAGACAGCGAGTGGTGTTGAT-
GAT-3' (P7), and reverse primer, 5'-CAGATCATCAACAC-
CACTCGCTGTCTCAATGCCACA-3' (P8), and designated
plasmid XI. The Ala mutation sites in P7 and P8 are itali-
cized. The thrombin recognition site was successfully
inserted into the plasmid XI background with the meg-
aprimer method. N- and C-terminal megaprimers were
prepared using the forward primer, P1, and reverse
primer, 5'-TATTTTATGACACGCCATGTCGCT-
GCCGCGCGGCACCAGATCATCAACACCACT-3' (P9), as
well as the forward primer, 5'-
ACAGACAGTGGTGTTGATGATCTGGTGCCGCGCG-
GCAGCGACATGGCGTGTCATAAA-3' (P10) and reverse
primer, P2, respectively. The thrombin recognition sites
are italicized. Each prepared megaprimer was extended by
PCR, using the other as a template, and the resulting prod-
uct inserted into the NdeI and XhoI sites of pET21a (desig-
nated plasmid V).
Preparation of recombinant caspase-3 precursors
E. coli BL21 Rosetta cells (Novagen) containing the speci-
fied expression plasmids were grown at 37°C in LB
medium until an A600 of 0.6–0.8. Engineered caspase-3
precursors were expressed by adding 1 mM IPTG at 18°C
for 18 h. Cells were harvested, washed with buffer A (50
mM Tris pH 7.5, 250 mM NaCl, 5% glycerol, and 0.05%
β-mercaptoethanol), and lysed by ultrasonication. After
centrifugation (29,820 g for 30 min), the supernatant was
incubated with a cobalt affinity resin (TALON®, Clontech)
on a rocker at 4°C for 1 h, and washed with buffer A con-
taining 10 mM imidazole. Proteins were eluted from the
metal affinity resin with buffer A supplemented with 100
mM imidazole. Following dialysis against 20 mM Tris, pH
7.5, 250 mM NaCl, 5% glycerol, and 1 mM dithiothreitol,
caspase-3 precursors were concentrated to 2 mg/ml and
stored at -80°C.
Activation of caspase-3 precursors by thrombin
Caspase-3 precursors were activated by digestion with
bovine thrombin. Briefly, 100 μg of each precursor pro-
tein was incubated with 1 NIH unit of thrombin in 50
mM Tris, pH 7.5, 250 mM NaCl, 5% glycerol, 0.05% β-
mercaptoethanol, 3 mM CaCl2 at 4°C. Digestion was per-
formed for 18 h, and monitored by 15% SDS-PAGE.
Treatment of caspase-3 precursors with wild-type caspase-
3
Caspase-3 precursors were treated with wild-type caspase-
3 to test autocleavage during activation. Briefly, 100 μg of
each precursor protein was incubated with 1 μg of wild-
type caspase-3 in 50 mM Tris, pH 7.5, 250 mM NaCl, 5%
glycerol, 0.05% β-mercaptoethanol, and 5 mM DTT at RT.
Cleavage was performed for 18 h, and monitored by 15%
SDS-PAGE.
Determination of caspase-3 activity and kinetic constants
The activity of each caspase-3 protein was measured using
the colorimetric substrate, Ac-DEVD-pNA. Briefly, cas-
pase-3 was activated in reaction buffer (50 mM HEPES,
pH 7.4, 50 mM KCl, 2 mM MgCl2, 1 mM EDTA, and 5 mM
dithiothreitol) for 18 h before use. The appropriate
amount of activated caspase-3 (final concentrations of
10–80 nM) was added to the substrate solution at a series
of final concentrations (0, 12.5, 25, 50, 100 and 200 μM).
The p-nitroanilide released by the caspase reaction was
monitored at 405 nm using a DU 800 UV-VIS Spectropho-BMC Biotechnology 2008, 8:92 http://www.biomedcentral.com/1472-6750/8/92
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tometer (Beckman Coulter). Km  and  Vmax  values were
obtained using Hyper32 version 1.0.0 http://
homepage.ntlworld.com/john.easterby/hyper32.html,
and kcat values calculated from Vmax and the used enzyme
concentration.
Cleavage of endogenous PARP by engineered caspases
Human promyelocytic leukemia HL60 cells were cultured
in RPMI. If necessary, apoptosis was induced by treatment
of the cells with 100 μM etoposide for 12 h. Cell lysates
(60 μg) were incubated with engineered caspases at 37°C
for 2 h. Then, the cleavage of endogenous PARP was deter-
mined by immunoblot analysis with an anti-PARP anti-
body. For negative control, cell lysates treated together
with engineered caspases and z-DEVD-fmk  were used
[26,27].
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